Community Health Status Affects Survival Post HCT
Investigators calculated patient community risk scores and center community risk scores to study the impact of community factors on patient outcomes following hematopoietic stem cell transplant.
All articles by Jessica Wapner
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Oral Oncology Parity Laws Don’t Make Medications More Affordable
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Why Cardiac Toxicity Should Not Prevent the Use of Ibrutinib for CLL or SLL
Final results of a landmark trial confirm the efficacy of ibrutinib for CLL and SLL—and while cardiovascular issues remain a concern, the benefits appear to outweigh the risks.
Study of Ibrutinib in CLL Shows a Benefit, but Raises Crucial Questions
The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.
PET Score Could Allow Patients to Avoid Unnecessary Treatment for Hodgkin Lymphoma
Interpreting PET scores according to established criteria is crucial for guiding treatment following initial chemotherapy in early-stage disease.
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
Despite its limitations, ctDNA is emerging as a potentially powerful diagnostic tool.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...